Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin delayed-release in papulopustular rosacea with positive lactulose breath test
2017-003722-33Phase 2Completed
- Sponsor
- Alfasigma
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in papulopustular rosacea comparing Rifaximin delayed-release with Placebo (2 arms). Primary endpoint: Co-primary efficacy endpoints. Started Jan 2018; status: completed.
02
Drugs
rifaximin
03
Conditions
papulopustular rosacea
Beyond the preview
Go deeper on 2017-003722-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003722-33.